Navigation Links
MonoSol Rx Issued Strategic US Patent Governing the Production of Pharmaceutical Films Containing Specific Drugs and Drug Classes
Date:4/4/2011

WARREN, N.J., April 4, 2011 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,897,080 from the United States Patent and Trademark Office (USPTO). The patent provides intellectual property protection for the Company's methods of pharmaceutical film preparation along with the incorporation of specific drugs and polymer components.

Among the active categories covered in the patent are opiate and opiate derivatives such as buprenorphine and naloxone, anti-emetics such as ondansetron and granisetron hydrochloride, analgesics such as fentanyl, anti-migraines such as triptans, and anti-diabetics.  Polymer components covered by the patent include carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and polyethylene oxide.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "This latest patent provides undeniable affirmation that MonoSol Rx has the leading IP position in the development of pharmaceutical films and that our PharmFilm® technology is the industry standard for film drug delivery.  Not only does this patent cover numerous actives and polymer components, but it also ensures that MonoSol Rx has process protection for the manufacturing of single and multi-layer films delivering a wide range of drug classifications through buccal and sublingual administration."  

Mr. Schobel continued, "Coupled with our prior patents, MonoSol Rx's growing intellectual property portfolio offers clear competitive advantages to our current and prospective partners who view PharmFilm® as an ideal vehicle for delivering small or large molecules as well as sensitive prescription drug targets."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® te
'/>"/>

SOURCE MonoSol Rx
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
2. MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010
3. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
4. MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
5. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
6. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
7. Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
8. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
9. Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued
10. Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate
11. Sixth U.S. Patent Issued to Dyadic International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: ... today announced financial results for the third quarter ... corporate, commercial, regulatory and clinical development updates from ... pleased with the continued momentum and strong performance ... this quarter, especially the XIAFLEX franchise, which more ...
(Date:10/30/2014)...  TWi Pharmaceuticals, Inc. today announced that it has ... Drug Administration (FDA) on its Abbreviated New Drug Application ... generic equivalent to Eisai Inc.,s Aricept® 23mg.  Aricept® 23mg ... TWi Pharmaceuticals is preparing to launch the product in ... USA , at the earliest time ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... EntreMed, Inc. (Nasdaq: ENMD ) announced today that ... with YA Global Master SPV Ltd. ("YA Global"), a fund ... has the option, at its sole discretion, to sell, from ... to YA Global.  Concurrent with the signing of the SEDA, ...
... NEWPORT NEWS, Va., June 28, 2011  Burlington Medical ... new product into its inventory. The Single Swing-Arm Drape ... protects the worker from any scattered beams of radiation ... The black vinyl drape is 39-and-a-half inches wide ...
Cached Medicine Technology:EntreMed Enters into $7.5 Million Equity Facility and Initiates $1.1 Million Drawdown 2EntreMed Enters into $7.5 Million Equity Facility and Initiates $1.1 Million Drawdown 3EntreMed Enters into $7.5 Million Equity Facility and Initiates $1.1 Million Drawdown 4Burlington Medical Supplies Introduces Single Swing-Arm Drape 2
(Date:10/30/2014)... TX (PRWEB) October 30, 2014 ... released today its 2014 third quarter infection rates ... Texas boasted infection rates of only two percent ... patient satisfaction scores exceeding 98 percent. , “We ... quarter, which included rising satisfaction scores,” said Robert ...
(Date:10/30/2014)... News) -- Scientists who used stem cells to create ... could provide a new way to learn more about ... team used human pluripotent stem cells -- which can ... to grow the functional miniature stomachs, to study infection ... of ulcers and stomach cancer. The miniature stomachs ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Many U.S. colleges ... even though tanning increases the risk for skin ... young adults, particularly white women, so colleges should ... the researchers said. "Public health efforts are ... awareness of the harms that indoor tanning poses ...
(Date:10/30/2014)... A new vaccine that could help prevent some cases ... U.S. Food and Drug Administration on Wednesday. Trumenba ... 10 and 25 from invasive meningococcal disease caused by ... bacteria can infect the bloodstream (sepsis) and the lining ... a leading cause of bacterial meningitis, and infection can ...
(Date:10/29/2014)... and even non-invasive technologies is increasing in the medical ... out a range of operative procedures using keyhole surgery ... scars as a result. Similar opportunities are now becoming ... – instead of using injections or probes to deliver ... them via a plaster which continuously, gently and painlessly ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... 25 OPKO Health, Inc. (Amex: OPK ),today ... C.,Pfenniger, Jr. to its Board of Directors. The company ... Mr. Pfenniger was,appointed to fill the vacancy created by ... created Board position., "The addition of Tom Beier ...
... $154 million, Announces Full Year 2008 Revenue Guidance of $204 ... and Reiterates ... Inc. (Nasdaq:,NUVA), a medical device company focused on developing products ... financial results for the full year ended December,31, 2007 and ...
... HOLLYWOOD, Calif., Jan. 25 IPC The,Hospitalist Company, Inc. ... announced yesterday the initial public offering of 5,200,000,shares of ... of $16.00 per share.,The Company has agreed to sell ... agreed to sell the remaining 1,900,000 shares of,common stock. ...
... Baxa Corporation announces,the launch of a targeted campaign ... delivery of quality therapy to patients, promoting,research and ... patients receiving IV therapy. The new campaign is ... Nurses Day. That day -- January 25, 2008 ...
... many as 30,000 deaths each year, study says , , ... contraceptives greatly reduce their risk of developing ovarian cancer, and ... new study confirms. , The use of oral contraceptives has ... cancer. The authors of the new study say their findings ...
... SAN DIEGO, Jan. 25 Plans put forward ... to healthcare will prove,impractical without more physicians and ... and Nurse Supply: The Missing Piece of the ... Healthcare, the largest,healthcare staffing company in the United ...
Cached Medicine News:Health News:OPKO Health Announces Changes to Board of Directors 2Health News:OPKO Health Announces Changes to Board of Directors 3Health News:NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 2Health News:NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 3Health News:IPC The Hospitalist Company, Inc. Prices Initial Public Offering 2Health News:Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock(R) Set Saver 2Health News:Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock(R) Set Saver 3Health News:Oral Contraceptives Cut Ovarian Cancer Risk 2Health News:Oral Contraceptives Cut Ovarian Cancer Risk 3Health News:Report: Too Few Physicians, Nurses to Implement Presidential Candidates' Health Reform Plans 2Health News:Report: Too Few Physicians, Nurses to Implement Presidential Candidates' Health Reform Plans 3
... Ankle Orthosis enables the clinician to ... ankle joint to control muscle imbalance ... a pair of bilateral turnbuckles, controlling ... Simply adjust the turnbuckle to gradually ...
... Protection,Protects the heel while maintaining the ankle ... contact with a soft, cushioning AliPlast™ foam ... and liner cradles the heel in a ... change position freely in bed from side-lying ...
... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
SCD Sequential Compression System Intermittent Pneumatic Compression...
Medicine Products: